Anti-CTLA-4 antibody added to IL-6 blockade augmented clinical benefit in murine solid tumor models, with increased CD8 + T cell tumor infiltration, T helper (Th) 1 cytokines, CXCL10, and CXCL11, and reduced infiltration of regulatory T cells (Tregs), Th17, macrophages, and myeloid-derived suppressor cells (MDSCs). The gene discussed is CD8A; the disease is neoplasm.